Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain their study's implications for providers and how age plays a role in genetic variant penetrance.
Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain their study's implications for providers and how age plays a role in genetic variant penetrance.
Transcript
What do providers need in order to understand what should happen next if a positive result does come back on a genetic test?
Forrest: This is an important question because, as clinicians, the highly relevant question in translation of this study would be, "what are the implications for me when I obtain a genetic test for my patients?" What we hope in our aspiration is that penetrance or these quantitative estimates of risk for disease with variants will one day be able to better guide clinicians when they stratify and assess the risk of their patients. I would add that genetic test results right now, if a variant that's pathogenic is identified, it should be understood that they actually might have low, medium or high probability of disease, AKA a wide range of penetrance. Future study is needed to refine these estimates of disease risk, and hopefully test whether changes in clinical care are warranted based on the penetrance of an individual's pathogenic variants.
How does an individual’s age intersect with the results you found?
Do: Age of onset for diseases is relevant for penetrance, and this is because early onset diseases will manifest in both younger and older individuals, while late onset diseases will only manifest in older individuals. We looked at this in our study and found that penetrance increased for late onset diseases when examining higher age vessels. Conversely, for early onset diseases, penetrance remained the same across all different age thresholds.
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More
An Elevated Member Experience, More Education, and Martha Stewart at the AAD 2025 Annual Meeting
March 4th 2025Seemal R Desai, MD, FAAD, president of the American Academy of Dermatology (AAD), emphasized his commitment to enhancing the upcoming 2025 annual meeting by introducing new events and expanding educational offerings to better serve and engage members.
Read More